Condoliase for treatment of lumbar disc herniation
-
Matsuyama, Y. [1] ; Chiba, K. [2]
-
[1] Hamamatsu University
Hamamatsu University
Naka-ku, Japón
-
[2] National Defense Medical College
National Defense Medical College
Minuma-ku, Japón
-
- Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 55, Nº. 1, 2019, págs. 17-23
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Lumbar disc herniation (LDH) is generally treated with a conservative therapy, and surgery is the only therapeutic option currently available for patients unresponsive to the conservative therapy. In the 1980s, chemonucleolysis with chymopapain, a protease, was widely used as the intermediate treatment between conservative therapy and surgical therapy in the Western countries. However, since chymopapain was withdrawn from the market in 2002 for non-scientific commercial reasons, chemonucleolysis has not been a therapeutic option for LDH. Condoliase (chondroitin sulfate ABC endolyase), a glycosaminoglycan-degrading enzyme, was approved by the drug regulatory authority in Japan as a newer intradiscal therapy for LDH after clinical studies conducted in Japan demonstrated efficacy and safety for patients with LDH. This review will focus on the preclinical pharmacology, pharmacokinetics, efficacy and safety of condoliase as a new option for treatment of LDH.
